ECR 2024 - Cancer Care Day
Dive into the forefront of lung cancer management at our symposium “Interdisciplinary perspectives in lung cancer: advancements in screening modalities and surgical implications“.
Lung Cancer
Targeting lung cancer
A profound understanding of the facetted characteristics and behavior of a tumor demands deep and integrated knowledge among clinical experts collaborating in interdisciplinary teams – a joint effort to empower personalized cancer care. By strategically combining advanced imaging, IT, and laboratory applications, lung cancer management can be improved through:
- Early detection through screening programs to reduce lung cancer related mortality
- Advanced lung cancer imaging to better visualize and characterize a tumor
- Innovative treatment planning and management for improved outcomes and reduction of side effects
- Individualized patient treatment and systematic assessment of therapy response to ensure treatment success
Whatever the clinical question, our innovative portfolio contains everything you need to offer patient care at the highest-possible level – from angiography, X-ray systems, MRI, CT, PET/CT, MR/PET, SPECT/CT, and clinical chemistry testing, through to interventional imaging, radiation oncology support, and systems designed for process optimization and efficient lung cancer workflows.
Explore on the following tabs how our advanced technologies and solutions help you look closer and see further – along the entire continuum of care.
Early detection & diagnosis
Treating late-stage lung cancer is extremely challenging. However, lung cancer treatment can be significantly more effective if the disease is detected earlier in stage I or II, before the onset of symptoms when the disease is still localized. This emphasizes the benefit to establish screening programs for earlier detection. Precise lung cancer staging of lymph node involvement and distant metastases determines the prognosis and is the foundation of adequate therapy selection.
Find out more about the benefits of lung cancer screening and its life-saving potential
Discover our imaging solutions
Therapy
Lung cancer is a leading cause of death with over 2 Million new cases per year and over 1.7 Million deaths per year9. Because it is asymptomatic it is detected often too late with a poor survival prognosis: The 5-year survival rate is about 57% for patients with stage 1 disease and only ~4% for those with stage 410
With the implementation of lung cancer screening protocols for patients at risk, lung cancer can be detected in an early stage which could drastically improve survival chances11. Therefore, minimally-invasive treatment options with curative intent will come more and more into focus. Key-hole surgery, robotic interventions, local thermal ablation, hybrid approaches, navigation technology and targeted radiation therapy are currently investigated by leading hospitals. Consequently, patients will ask for these options.
Discover our therapy solutions
Early stage lung cancer imposes challenges on therapy because of small targets and the natural deviation between accurate diagnostic findings and the situation during surgery, intervention or radiotherapy12. Siemens Healthineers provide image-guided solutions for non- and minimally- invasive lung cancer therapy to face these challenges. Many factors are impacting clinical outcomes. However, our vision is to contribute with our technology to lower survival rates, less complications and a better quality of life of cancer patients.
In particular, our robotic C-arm ARTIS pheno supports one-stop image-guided localization and resection of small pulmonary nodules in the Hybrid OR 13. Endobronchial interventions are supported cost efficiently with our mobile 3D C-arm Cios Spin.14 Planning of stereotactic body-radiation therapy is supported through dedicated multi-modality imaging through our dedicated CT system SOMATOM go.Open Pro. For lung metastasis and medically inoperable patients image-guided percutaneous thermal ablation can potentially reduce the tumor burden 15. Artis Q ceiling has the tools for such procedures.
Monitoring & follow-up
Therapy monitoring and follow-up of lung cancer are key to individualized patient treatment. Monitoring the tumor’s response allows a timely adaptation to the selected therapy. This is important when several therapeutic options are available, as is the case with lung cancer.
After completion of the therapy, a systematic follow-up for the early detection of lung cancer relapse should always be part of the patient’s workup and is described in the corresponding guidelines.
Further insights
Vond u deze informatie nuttig?
1
syngo.via can be used as a stand-alone device or together with a variety of syngo.via-based software options, which are medical devices in their own right.
2
De Koning, H. J., Van Der Aalst, C. M., De Jong, P. A., Scholten, E. T., Nackaerts, K., Heuvelmans, M. A., … Oudkerk, M. (2020). Reduced lung-cancer mortality with volume CT screening in a randomized trial. https://www.nejm.org/doi/full/10.1056/NEJMoa1911793 (last accessed 14 April 2020)
3
Lung Cancer Screening CT Protocols Version 5.1. 24 July 2019, provided by AAPM, American Association of Physicists in Medicine https://www.aapm.org/pubs/CTProtocols/documents/LungCancerScreeningCT.pdf (last accessed 14 April 2020)
4
Indication for low dose lung cancer screening is applicable to the following scanner models: SOMATOM Force, SOMATOM Drive, SOMATOM Definition Edge, SOMATOM Edge Plus, SOMATOM X.cite, SOMATOM go.Top, SOMATOM go.All, SOMATOM go.Up, SOMATOM go.Now
5
for selected scanners
6
British Thoracic Society guidelines for pulmonary nodules. https://thorax.bmj.com/content/70/Suppl_2/ii1 (last accessed 14 April 2020)
7
Based on volumetric resolution available in competitive literature for systems greater than 70 cm bore size. Data on file.
8
DotGo Workflow for Biograph mMR is still under development and not commercially available yet. Its future availability cannot be ensured.
9
WHO, Global Cancer Observatory, Lung Cancer Fact Sheet, 2019
10
Miller et al. CA Cancer J Clin 2019;69:363–385
11
National Lung Screening Trial Research Team. N Engl J Med 2011;365:395-409
12
Pritchett et al. J Thorac Dis 2020
13
Gill et al. J. Surg. Oncol. 2015;9999:1–8.
14
Gildea et al. J Bronchol Intervent Pulmonol 2020;27(2):153-155
15
Vogl et al. Eur J Radiol 2011 Feb;77(2):346-57
16
Casal et al. Cone beam computed tomography-guided thin/ultrathin bronchoscopy for diagnosis of peripheral lung nodules: a prospective pilot study. J Thorac Dis 2018
17
Gildea et al. Multidimensional Precision Hybrid Mobile 2D/3D C-Arm Assisted Biopsy of Peripheral Lung Nodules. J Bronchol Intervent Pulmonol 2020
18
Chao et al. J Thorac Cardiovasc Surg 2020;156:1974-1983. 1-step hybrid OR workflow compared to a 2-step/2-room CT-based workflow
19
Image by courtesy of Olivier Pellerin, Interventional Radiology, HEGP, Paris, France
20
Hohenforst-Schmidt et al. J Canc 2014;5:192-202
21
Kostrzewa et al., Accuracy of percutaneous soft-tissue interventions using a multi-axis C-arm CT system and 3D laser guidance, Eur J Radiol. 2015;84:1970–1975
22
Image by courtesy of Leopoldina Hospital Schweinfurt, Germany. Rendering not generated with syngo.via
23
Image by courtesy of Leopoldina Hospital Schweinfurt, Germany. Rendering not generated with syngo.via
24
https://www.siemens-healthineers.com/radiotherapy/ct-for-rt/somatom-go-sim#ADD_INFO